Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolysis beyond the three-hour time window.

Didier Leys1, Dominique Deplanque

  • 1Cognitive Decline in Degenerative and Vascular Disorders, University of Lille, Lille, France. dleys@chru-lille.fr

Clinical and Experimental Hypertension (New York, N.Y. : 1993)
|July 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunological efficacy and safety of influenza vaccination in adults with sarcoidosis: the SARCOVAC study.

Vaccine·2026
Same author

Combination of Clopidogrel With PPIs or P-CABs: Beware of Risky Interactions.

Stroke·2026
Same author

Comparison of the effect of donepezil and a combination of donepezil and mefloquine (THN201) on cognition during a scopolamine challenge in healthy participants.

Experimental and clinical psychopharmacology·2026
Same author

Being 80 years old in a rapidly changing world….

Therapie·2026
Same author

More Pragmatic, Randomized Clinical Trials Are Needed to Improve Quality of Evidence in Stroke Guidelines.

Stroke·2026
Same author

Accelerating recruitment in clinical trials: A strategic challenge.

Therapie·2026

Intravenous thrombolysis using tissue plasminogen activator (rt-PA) shows effectiveness up to 6 hours, though benefits decrease over time. Advanced imaging can help select patients for treatment beyond the initial 3-hour window.

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Medical Imaging

Background:

  • Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) was approved in Europe in 2002 within a 3-hour window.
  • Meta-analyses indicate potential efficacy of rt-PA for up to 4.5 to 6 hours post-stroke.

Purpose of the Study:

  • To evaluate the efficacy of rt-PA thrombolysis beyond the established 3-hour time window.
  • To explore advanced imaging techniques for patient selection in extended time windows.

Main Methods:

  • Review of meta-analyses of intravenous rt-PA trials.
  • Discussion of magnetic resonance imaging (MRI) for identifying arterial occlusion and diffusion-perfusion mismatch.
  • Overview of ongoing and planned clinical trials for extended thrombolysis.

Related Experiment Videos

Main Results:

  • Treatment efficacy of rt-PA declines significantly after 3 hours.
  • Numbers needed to treat increase substantially in later time windows (0-6 hr and 3-6 hr).
  • MRI may identify suitable candidates for thrombolysis beyond 3 hours.

Conclusions:

  • The 3-hour time limit for rt-PA is primarily a safety consideration.
  • Early treatment is crucial, with benefits diminishing rapidly over time.
  • Further research and trials are investigating extended time windows and alternative thrombolytic methods.